MARKET WIREYahoo! Finance Canada • 22h ago
RedHill Biopharma Ltd. (RDHL) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering Redhill Biopharma Ltd. (RDHL) market action, institutional positioning, and fundamental catalysts.
Why RDHL Stock surged +13.87% Today — RQD Quant Desk Flash
$0.44 +13.87% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.45
Redhill Biopharma Ltd. (RDHL) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $3.4M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on RDHL Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is RDHL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Redhill Biopharma Ltd. (NASDAQ: RDHL) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $0.44 (+13.87% 1D, market cap $3.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, RDHL ranks #249 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does RDHL compare to CVKD and GRI in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RDHL carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CVKD (Cadrenal Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.5M) and GRI (GRI Bio Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.3M). Among the 5-stock peer group, RDHL leads on earnings multiple (N/A) while CVKD leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for RDHL?
▼
For Redhill Biopharma Ltd. (RDHL), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #249 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.45 (+2.31%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY • 50.1% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D+ · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-2.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RDHL)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (52/100 Composite)
🔍 WHY RDHL SCORES 52/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (25% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (23% of score)
SEC XBRL Trailing 12 Months: 0% FCF Margin ($96.5K FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Macro Regime Fit8/20 pts (-12 pt drag)
Macro rate sensitivity & RSI-14 (36.4) create a -12 pt regime headwind
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$0.51+0% Next Q
60
Q2 (-2Q)Grade C$0.51-11.8% Next Q
57
Q3 (-1Q)Grade C$0.45-2.2% Next Q
55
CurrentGrade D+$0.44-1.1% Hist 90D α
52
Trajectory: C (60) → D+ (52)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a RDHL Turnaround Squeeze
While RDHL currently carries a cautious 52/100 (D+) rating due to Macro Regime Fit (8/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.55) and Max Pain ($0.46) forces dealer call-delta covering toward $1.68.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $RDHL• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RDHL Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why RDHL Stock surged +13.87% Today — RQD Quant Desk Flash
Redhill Biopharma Ltd. (RDHL) surged +13.87% to $0.44, trading at 5% of its 52-week range ($0.38 – $1.6). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 5% of its 52-week range ($0.38 – $1.6) with RSI-14 at 36.4 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.44 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 52% gross margin and $96506 annual free cash flow.
Live RDHL Headlines & Catalysts
MARKET WIREStock Titan • 1d ago
Each depositary share represents 10,000 ordinary shares at RedHill Biopharma (RDHL).Stock Titan report covering Redhill Biopharma Ltd. (RDHL) market action, institutional positioning, and fundamental catalysts.
RISK WATCHPR Newswire • 1d ago
$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple MyelomaPR Newswire report covering Redhill Biopharma Ltd. (RDHL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Drug rights return to RedHill Biopharma (RDHL) as Hyloris agrees to a $200,000 break-up fee.Stock Titan report covering Redhill Biopharma Ltd. (RDHL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 1d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market SessionBenzinga report covering Redhill Biopharma Ltd. (RDHL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 1d ago
Redhill Biopharma (RDHL) Pressured Near $0.42 as Shares Test Lower Support - Symmetrical Trianglehttps://www.siam.in/ report covering Redhill Biopharma Ltd. (RDHL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Two lab studies test RedHill Biopharma (RDHL)’s Phase 2-ready Crohn’s candidate.Stock Titan report covering Redhill Biopharma Ltd. (RDHL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 1d ago
Two Leading Labs Confirm RHB-204 MAP-Killing Effect for RedHill's Crohn's Disease CandidateRedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the confirmation of RHB-204's killing capability on Mycobacterium avium subspecies paratuberculos
MARKET WIREBenzinga • 1d ago
Redhill Biopharma Announced Confirmation Of RHB-204's Killing Capability On Mycobacterium Avium Subspecies Paratuberculosis And Its Comparability To RHB-104 MAP-KillingIn vitro studies, undertaken by two leading microbiology centers, confirm RHB-204's killing capability on Mycobacterium avium subspecies paratuberculosis (MAP) and its MAP-killing comparability to RedHill's
MARKET WIREBenzinga • 7d ago
'Congo Ebola Cases Top 10,000 as Violence Hits Health Workers' - Bloomberghttps://www.bloomberg.com/news/articles/2026-10-27/congo-ebola-cases-top-10-000-as-violence-hits-health-workers
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RDHL)
- ✓Walkthrough of RDHL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
RDHL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -57.69%🛡️ HOLDING TREND SUPPORT
2026-11-03O $0.42H $0.44L $0.39C $0.44VOL 109.2K
RES: $1.95SUP: $0.37SMA50: $0.55SMA200: $0.80
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
RDHL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on RDHL today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for RDHL. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RDHL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RDHL)
Health Care Rank #249 of 1016
⚔️ CVKD vs RDHL Full Matrix →
1. Head-to-Head Health Care Peer Comparison (RDHL vs. CVKD, GRI, MDCX, ONCO)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Redhill Biopharma Ltd. (RDHL) ranks #249 by composite RQD confidence (52/100, grade D+) and #968 by equity capitalization ($3.4M). Within this direct 5-issuer industry benchmark cohort, RDHL leads on earnings valuation at N/A trailing P/E, while CVKD leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. RDHL currently leads its immediate peer cohort in composite quantitative strength at 52/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| RDHL
ACTIVE
Redhill Biopharma Ltd. | D+ | 52/100 | — | — | — | +13.87% | $3.4M | Benchmark Subject |
| CVKD Cadrenal Therapeutics Inc. | E | 34/100 | — | — | -35.0% | +5.58% | $3.5M | /cvkd-vs-rdhl → |
| GRI GRI Bio Inc. | E | 34/100 | — | — | -35.0% | -4.57% | $3.3M | /gri-vs-rdhl → |
| MDCX Medicus Pharma Ltd. | E | 34/100 | — | — | -35.0% | +2.66% | $3.6M | /mdcx-vs-rdhl → |
| ONCO Onconetix Inc. | E | 30/100 | — | 77.6% | -35.0% | -3.24% | $3.3M | /onco-vs-rdhl → |
2. RDHL Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTRedhill Biopharma Ltd. (RDHL) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $3.4M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. RDHL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs RDHL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Redhill Biopharma Ltd. (NASDAQ: RDHL) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $0.44 (+13.87% 1D, market cap $3.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, RDHL ranks #249 in composite RQD confidence.
How does RDHL compare to CVKD and GRI in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RDHL carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CVKD (Cadrenal Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.5M) and GRI (GRI Bio Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.3M). Among the 5-stock peer group, RDHL leads on earnings multiple (N/A) while CVKD leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for RDHL?
For Redhill Biopharma Ltd. (RDHL), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #249 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is RDHL trading relative to its 50-day, 200-day, and 52-week technical levels?
RDHL last traded at $0.44 (+13.87% on volume of 313,549 shares), positioning the stock -20.00% below its 50-day simple moving average ($0.55) and -45.00% below its 200-day simple moving average ($0.80). Across its 52-week range of $0.38 to $1.60, RDHL sits at the 4.9% percentile with a 14-day RSI of 36.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.50).
ROARABLE RATING BRIEF • RQD 52/100 (D+)
✓ SEC XBRL & RQD VERIFIED
RDHL — Redhill Biopharma Ltd.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03
1. Roarable Rating Brief: What This Means to a Prospective Investor
Redhill Biopharma Ltd. (RDHL) earns a live Roarable RQD composite score of 52/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $0.44 (+13.87% 1D, market capitalization $3.4M).
- Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (10/20) + Insider Conviction (13/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (8/20) + Forensic Balance Sheet (9/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Redhill Biopharma Ltd. (RDHL) is a NASDAQ-listed issuer in the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D+ • RQD 52/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 10/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $0.38 – $1.60 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), RDHL carries a macro regime beta of 1.00 and gross margin of —.
- Key Question #1: Can RDHL sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $1.60 52-week high?
- Key Question #3: How sensitive is RDHL's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
RDHL Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Redhill Biopharma Ltd. (RDHL) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo! Finance Canada • 22h ago
RedHill Biopharma Ltd. (RDHL) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering Redhill Biopharma Ltd. (RDHL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Each depositary share represents 10,000 ordinary shares at RedHill Biopharma (RDHL). Stock Titan report covering Redhill Biopharma Ltd. (RDHL) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH PR Newswire • 1d ago
$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma PR Newswire report covering Redhill Biopharma Ltd. (RDHL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Drug rights return to RedHill Biopharma (RDHL) as Hyloris agrees to a $200,000 break-up fee. Stock Titan report covering Redhill Biopharma Ltd. (RDHL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session Benzinga report covering Redhill Biopharma Ltd. (RDHL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 1d ago
Redhill Biopharma (RDHL) Pressured Near $0.42 as Shares Test Lower Support - Symmetrical Triangle https://www.siam.in/ report covering Redhill Biopharma Ltd. (RDHL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Two lab studies test RedHill Biopharma (RDHL)’s Phase 2-ready Crohn’s candidate. Stock Titan report covering Redhill Biopharma Ltd. (RDHL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo • 1d ago
Two Leading Labs Confirm RHB-204 MAP-Killing Effect for RedHill's Crohn's Disease Candidate RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the confirmation of RHB-204's killing capability on Mycobacterium avium subspecies paratuberculos
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
RDHL Bull vs. Bear Conversation Board — What's Your Call at $0.44?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RDHL 🐻 33% BEARISH CONVICTION
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH
🎯 Target: $0.46 (+17.9%)
📌 Pinned Debate Forensic balance-sheet pillar scores 13/20 with Altman Z of 2.5 and Piotroski F of 6/9, its strongest reading.
Don't sleep on RDHL's setup in Health Care. Forensic balance-sheet pillar scores 13/20 with Altman Z of 2.5 and Piotroski F of 6/9, its strongest reading.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (52/100) backs up the fundamental quality.
VolSurface_Trader 🐂 BULL
@MultipleCompression Shorting a 10/20 institutional whale-flow stock at $0.39 is dangerous when funds are rotating into Health Care.
MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH
🎯 Target: $0.31 (-20.5%)
Spot @ $0.39 Fundamental cash engine and macro fit score weakly, with ROIC and FCF yield both at 0% and Beta of 1.0.
Sitting on the sidelines or leaning short RDHL above $0.39. Fundamental cash engine and macro fit score weakly, with ROIC and FCF yield both at 0% and Beta of 1.0.. Until Fundamental Cash Engine (12/20) and FCF yield (0.0%) inflect higher, upside is capped near $1.60.